This Insider Has Just Sold Shares In Lyell Immunopharma
Anyone interested in Lyell Immunopharma, Inc. (NASDAQ:LYEL) should probably be aware that the Principal Executive Officer, Lynn Seely, recently divested US$149k worth of shares in the company, at an average price of US$15.54 each. That sale was 13% of their holding, so it does make us raise an eyebrow.
The Last 12 Months Of Insider Transactions At Lyell Immunopharma
In fact, the recent sale by Principal Executive Officer Lynn Seely was not their only sale of Lyell Immunopharma shares this year. They previously made an even bigger sale of -US$174k worth of shares at a price of US$23.39 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (US$14.80). So it may not shed much light on insider confidence at current levels.
In the last year Lyell Immunopharma insiders didn't buy any company stock. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Check out our latest analysis for Lyell Immunopharma
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
Insider Ownership
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 7.1% of Lyell Immunopharma shares, worth about US$27m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
So What Does This Data Suggest About Lyell Immunopharma Insiders?
Insiders sold Lyell Immunopharma shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. Insiders own shares, but we're still pretty cautious, given the history of sales. We'd practice some caution before buying! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Lyell Immunopharma. When we did our research, we found 6 warning signs for Lyell Immunopharma (2 are potentially serious!) that we believe deserve your full attention.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.